Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?  

This woman is among the 40-50% of patients with ER-positive/HER2-positive cancer who achieve pathological CR with neoadjuvant TCHP. The benefit of adding endocrine therapy to chemotherapy in this setting is unknown. Since the default is to give adjuvant endocrine therapy, many of the relevant neoadj...